Klostergaard J - Search Results

1

Arginine as a contact residue in the hapten-binding site of protein 315.

Klostergaard J, Krausz LM, Grossberg AL, Pressman D. Klostergaard J, et al. Immunochemistry. 1977 Feb;14(2):107-10. doi: 10.1016/0019-2791(77)90288-9. Immunochemistry. 1977. PMID: 852884 No abstract available.

2

Absence of lysine from the DNP-lysine binding site of protein 315; designation of lysine 52 of the heavy chain as a peripheral residue.

Klostergaard J, Grossberg AL, Krausz LM, Pressman D. Klostergaard J, et al. Immunochemistry. 1977 Jan;14(1):37-44. doi: 10.1016/0019-2791(77)90331-7. Immunochemistry. 1977. PMID: 403127 No abstract available.

3

Effect of iodination of ligand binding by protein 315; designation of a highly reactive light chain tyrosine as a contact residue.

Klostergaard J, Mayers GL, Grossberg AL, Pressman D. Klostergaard J, et al. Immunochemistry. 1978 Apr;15(4):225-30. doi: 10.1016/0161-5890(78)90059-7. Immunochemistry. 1978. PMID: 669745 No abstract available.

4

The use of protein A in solid-phase binding assays: a comparison of four radioiodination techniques.

Mayers GL, Klostergaard J. Mayers GL, et al. Among authors: klostergaard j. J Immunol Methods. 1983 Feb 25;57(1-3):235-46. doi: 10.1016/0022-1759(83)90083-2. J Immunol Methods. 1983. PMID: 6402549

5

BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues.

Sahin IH, Klostergaard J. Sahin IH, et al. Among authors: klostergaard j. JCO Oncol Pract. 2021 Dec;17(12):723-730. doi: 10.1200/OP.21.00160. Epub 2021 Jun 2. JCO Oncol Pract. 2021. PMID: 34077235 Review.

6

Precision medicine for metastatic colorectal cancer: an evolving era.

Guler I, Askan G, Klostergaard J, Sahin IH. Guler I, et al. Among authors: klostergaard j. Expert Rev Gastroenterol Hepatol. 2019 Oct;13(10):919-931. doi: 10.1080/17474124.2019.1663174. Epub 2019 Sep 3. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31475851 Review.

7

Magnetic resonance imaging contrast enhancement in vitro and in vivo by octanuclear iron-oxo cluster-based agents.

Das S, Parga K, Chakraborty I, Tinoco AD, Delgado Y, López PM, Fernández Vega L, Sanakis Y, Ghosh S, Bankson J, Klostergaard J, González-Méndez R, Raptis RG. Das S, et al. Among authors: klostergaard j. J Inorg Biochem. 2018 Sep;186:176-186. doi: 10.1016/j.jinorgbio.2018.06.005. Epub 2018 Jun 26. J Inorg Biochem. 2018. PMID: 29957454 Free PMC article.

8

TRIB2 contributes to cisplatin resistance in small cell lung cancer.

Liang Y, Yu D, Perez-Soler R, Klostergaard J, Zou Y. Liang Y, et al. Among authors: klostergaard j. Oncotarget. 2017 Nov 27;8(65):109596-109608. doi: 10.18632/oncotarget.22741. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312632 Free PMC article.

9

CD44 as a drug delivery target in human cancers: where are we now?

Sahin IH, Klostergaard J. Sahin IH, et al. Among authors: klostergaard j. Expert Opin Ther Targets. 2015;19(12):1587-91. doi: 10.1517/14728222.2015.1088834. Epub 2015 Sep 16. Expert Opin Ther Targets. 2015. PMID: 26374284

10

Targeting SH2 domains in breast cancer.

Morlacchi P, Robertson FM, Klostergaard J, McMurray JS. Morlacchi P, et al. Among authors: klostergaard j. Future Med Chem. 2014;6(17):1909-26. doi: 10.4155/fmc.14.120. Future Med Chem. 2014. PMID: 25495984 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters